Contact Us
Drug Search Results
More Filters [+]

RO-6870810

Alternative Names: ro-6870810, ro6870810, ro 6870810, ten-010, ten010, ten 010
Latest Update: 2021-11-23
Latest Update Note: PubMed Publication

Product Description

RO6870810 (formerly TEN-010) is a small molecule, bromodomain and extra-terminal (BET) bromodomain inhibitor. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02308761)

Mechanisms of Action: BET Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for RO-6870810

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Diffuse Large B-Cell Lymphoma|NUT Carcinoma|Large Cell Carcinoma|Small Cell Carcinoma|Acute Myeloid Leukemia|Ovarian Cancer|Triple Negative Breast Cancer|Multiple Myeloma|Myelodysplastic Syndrome|Preleukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NP39403

P1

Completed

Multiple Myeloma

2019-08-01

41%
NP39461

P1

Completed

Diffuse Large B-Cell Lymphoma

2019-07-03

43%
NP39487

P1

Terminated

Triple Negative Breast Cancer|Ovarian Cancer

2019-02-26

41%
NP39141

P1

Completed

Large Cell Carcinoma|Diffuse Large B-Cell Lymphoma|NUT Carcinoma|Small Cell Carcinoma

2017-10-11

Recent News Events

Date

Type

Title

11/23/2021

PubMed

 Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.

09/03/2021

PubMed

 A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.

07/01/2021

PubMed

 A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions